Emcure Pharmaceuticals Limited
All news and filings related to Emcure Pharmaceuticals Limited.
View all news & filings- Low impact
Emcure Pharmaceuticals Announces Trading Window Closure from Oct 01, 2026
Emcure Pharmaceuticals Limited will close its trading window from October 01, 2026, until 48 hours after the declaration of Q2 FY27 unaudited financial results. The board meeting date for results approval will be announced later.
Read the summary - High impact
Emcure Pharmaceuticals FY26 Revenue Grows 16.6% to ₹92,035 Crore; PAT Up 33.1%
Emcure Pharmaceuticals reported FY26 revenue of ₹92,035 Crore, up 16.6% YoY. PAT increased 33.1% to ₹9,413 Crore. International business grew 22.2% to ₹51,766 Crore. Q1 FY27 revenue rose 22.8% to ₹25,804 Crore, with PAT up 36.2% to ₹2,925 Crore.
Read the summary - Medium impact
Emcure Pharmaceuticals Announces Board Changes Post AGM, Including Director Retirements and Re-appointments
Emcure Pharmaceuticals announced board changes post its 45th AGM on September 21, 2026. Key changes include the retirement of Chairman Mr. Berjis Desai and re-appointments of Dr. Mukund Gurjar (Whole-time Director) and Mr. Satish Mehta (MD & CEO). Mr. Raghu Kumar was appointed as an Independent Director.
Read the summary - Low impact
Emcure Pharmaceuticals Ltd. Reports Successful AGM Voting Results
Emcure Pharmaceuticals Limited held its 45th AGM on September 21, 2026. All resolutions presented, including director appointments and auditor remuneration, were approved by shareholders with the required majority. The voting results and scrutinizer's report have been submitted to stock exchanges.
Read the summary - Medium impact
Emcure Pharmaceuticals Holds 45th AGM, Approves Dividend and Director Appointments
Emcure Pharmaceuticals held its 45th AGM on September 21, 2026, approving the FY26 financial statements and a final dividend of ₹3.60 per share. Key appointments and re-appointments of directors were confirmed, including Mrs. Namita Thapar, Mr. Satish Mehta, and Mr. Raghu Kumar. Mr. Berjis Desai retired as Chairman.
Read the summary - Low impact
Emcure Pharmaceuticals to hold 45th AGM on Sep 21, 2026; Annual Report 2025-26 available
Emcure Pharmaceuticals will hold its 45th AGM on September 21, 2026, via video conference. The Annual Report for FY 2025-26 is available online. Members must submit TDS exemption documents by September 14, 2026, for final dividend eligibility.
Read the summary - Low impact
Emcure Pharmaceuticals to Participate in Investor Meeting on Sep 4, 2026
Emcure Pharmaceuticals will attend an investor meeting on September 04, 2026, in Pune. The meeting is with institutional investors and will be conducted physically. No unpublished price-sensitive information will be disclosed.
Read the summary - Medium impact
Emcure Pharmaceuticals' Credit Ratings Reaffirmed by CARE Ratings; Long-term Facilities at CARE AA; Stable
CARE Ratings reaffirmed Emcure Pharmaceuticals' credit ratings. Long-term bank facilities are rated CARE AA; Stable, and short-term facilities are rated CARE A1+. The company reported FY26 revenue of ₹9,322 crore, up 18% YoY, with a PBILDT margin of 20.0%. Emcure also acquired full ownership of Gennova Biopharmaceuticals.
Read the summary - Low impact
Emcure Pharmaceuticals Announces 45th AGM on Sep 21, 2026, with E-voting Facility
Emcure Pharmaceuticals will hold its 45th AGM on September 21, 2026, via Video Conference. Members can participate and vote remotely through an e-voting facility. The announcement was published in "Financial Express" and "Loksatta" on August 29, 2026.
Read the summary - Low impact
Emcure Pharma Announces 45th AGM on Sep 21, 2026; Annual Report FY26 Released
Emcure Pharmaceuticals Limited will hold its 45th AGM on September 21, 2026, via VC/OAVM. The Annual Report for FY 2025-26 is released. Remote e-voting is open from September 18-20, 2026. FY26 highlights include ₹92,035 million revenue and ₹9,413 million PAT.
Read the summary - High impact
Emcure Pharma Q1 FY27 Earnings Call Transcript Released; Key Management Changes Announced
Emcure Pharmaceuticals released its Q1 FY27 earnings call transcript. Key management changes include Satish Mehta taking over as Chairman and Samit Mehta appointed COO. Emcure acquired full ownership of Gennova. Q1 FY27 revenue grew 22.8% to ₹2,580 crore, with PAT up 36.2% to ₹292 crore. The company expects low to mid-teen revenue growth in FY27.
Read the summary - Medium impact
Emcure Pharmaceuticals Receives USFDA Establishment Inspection Report, Inspection Closed as VAI
Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the USFDA for its Sanand, Gujarat facility. The USFDA has classified the inspection as Voluntary Action Indicated (VAI), and the inspection is now closed. This follows an inspection conducted from May 06 to May 15, 2026.
Read the summary - Low impact
Emcure Pharmaceuticals Announces Schedule of Investor Meetings from Aug 12 to Sep 22
Emcure Pharmaceuticals will participate in multiple investor meetings and conferences from August 12 to September 22, 2026. Key events include the Emkay ‘Confluence 2026’, Motilal Oswal Global Investor Conference, Elara India Dialogue, Kotak Healthcare Forum, and J. P. Morgan India Conference. No price-sensitive information will be shared.
Read the summary - Low impact
Emcure Pharmaceuticals Announces Schedule of Investor Meetings from August to September 2026
Emcure Pharmaceuticals will participate in several investor and analyst meetings from August 12 to September 22, 2026. Key events include the Emkay 'Confluence 2026', Motilal Oswal Global Investor Conference, Elara India Dialogue, Kotak Healthcare Forum, and J.P. Morgan India Conference. No price-sensitive information will be disclosed.
Read the summary - Low impact
Emcure Pharmaceuticals Schedules Multiple Investor Meetings in August and September 2026
Emcure Pharmaceuticals will participate in several investor meetings and conferences from August 12 to September 22, 2026. Key events include Emkay Confluence 2026, Motilal Oswal Global Investor Conference, Elara India Dialogue 2026, Kotak Healthcare Forum 2026, and J. P. Morgan India Conference.
Read the summary - Low impact
Emcure Pharmaceuticals Announces Schedule of Investor Meetings for August and September 2026
Emcure Pharmaceuticals will participate in several investor conferences from August to September 2026. Key meetings include Emkay Confluence 2026 on August 12, Motilal Oswal Global Investor Conference on August 18, Elara India Dialogue on September 1, Kotak Healthcare Forum on September 17, and J.P. Morgan India Conference on September 22. No price-sensitive information will be shared.
Read the summary - Low impact
Emcure Pharmaceuticals Announces Schedule of Investor Meetings from August to September 2026
Emcure Pharmaceuticals has scheduled a series of investor meetings and conferences from August 12 to September 22, 2026. These include participation in Emkay Confluence 2026, Motilal Oswal Global Investor Conference, Elara India Dialogue, Kotak Healthcare Forum, and J.P. Morgan India Conference. No price-sensitive information will be shared.
Read the summary - Low impact
Emcure Pharmaceuticals Publishes Q1 FY27 Unaudited Financial Results
Emcure Pharmaceuticals Limited published its unaudited financial results for the quarter ended June 30, 2026. The results appeared in "Financial Express" and "Loksatta" on August 07, 2026, and are also available on the company's website.
Read the summary - Low impact
Emcure Pharmaceuticals Releases Audio Recording of Q1 FY27 Earnings Call
Emcure Pharmaceuticals Limited has released the audio recording of its Q1 FY27 earnings call, held on August 06, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Emcure Pharmaceuticals Announces 45th AGM on Sep 21, 2026, Sets Record Date for Final Dividend
Emcure Pharmaceuticals will hold its 45th AGM on September 21, 2026. The record date for the final dividend of ₹3.60 per share for FY26 is set for September 04, 2026. Dividend payment is expected within 30 days of AGM approval.
Read the summary - Medium impact
Emcure Pharmaceuticals Announces Board Changes: New Independent Director Appointed, Chairman to Retire
Emcure Pharmaceuticals announces board changes. Mr. Berjis Desai will retire as Chairman and Director post-AGM (Sept 21, 2026). Mr. Raghu Kumar appointed as Additional Independent Director from Aug 06, 2026. Mr. Satish Mehta to become Chairman post-AGM.
Read the summary - High impact
Emcure Pharmaceuticals Q1FY27 Results: Revenue Up 22.8% to ₹25,804 Crore, PAT Rises 36.2%
Emcure Pharmaceuticals reported Q1 FY27 results with revenue at ₹25,804 crore (up 22.8% YoY) and PAT at ₹2,925 crore (up 36.2% YoY). International business grew 34.2%. Mr. Satish Mehta to become Chairman, and Mr. Samit Mehta appointed COO. A conference call is scheduled for August 6, 2026.
Read the summary - High impact
Emcure Pharmaceuticals Q1 FY27: Revenue up 23% to ₹25,804 Mn, PAT rises 36% to ₹2,925 Mn
Emcure Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹25,804 Mn, up 22.8% YoY. PAT increased by 36.2% to ₹2,925 Mn. The company appointed Mr. Satish Mehta as Chairman and Mr. Samit Mehta as COO. Emcure also completed the acquisition of Gennova Biopharmaceuticals, making it a wholly owned subsidiary.
Read the summary - Medium impact
Emcure Pharmaceuticals Completes Acquisition of Gennova, Making it Wholly Owned Subsidiary
Emcure Pharmaceuticals has completed the acquisition of 12.05% of Gennova Biopharmaceuticals for ₹231.87 crore. This acquisition makes Gennova a wholly-owned subsidiary. Gennova reported a turnover of ₹491.74 crore for FY26.
Read the summary - Low impact
Emcure Pharmaceuticals: Independent Director P.S. Jayakumar Completes Term on July 21, 2026
Mr. P.S. Jayakumar will cease to be an Independent Director of Emcure Pharmaceuticals Limited effective July 21, 2026, upon completion of his second consecutive term. He will also step down as Chairman of the Audit Committee and member of Nomination and Remuneration and Risk Management Committees.
Read the summary - Medium impact
Emcure Pharmaceuticals to Expand Poviztra® Use for MASH Indication Post CDSCO Approval
Emcure Pharmaceuticals received CDSCO approval to expand Poviztra® (semaglutide) for MASH treatment in adults with liver fibrosis. This is the first GLP-1 receptor agonist approved in India for MASH. The approval follows positive Phase III ESSENCE trial results.
Read the summary - Medium impact
Emcure Pharma consolidates Gennova ownership to 100%; Samit Mehta to lead.
Emcure Pharmaceuticals acquires the remaining 12.05% stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary. Samit Mehta will lead Gennova, focusing on biologics and biosimilars. The transaction is not expected to materially impact Emcure's financials.
Read the summary - Medium impact
Emcure Pharmaceuticals to acquire 12.05% stake in Gennova Biopharmaceuticals
Emcure Pharmaceuticals will acquire an additional 12.05% stake in its subsidiary, Gennova Biopharmaceuticals, for ₹231.87 crore in cash. This will make Gennova a wholly-owned subsidiary. The deal is expected to close by July 31, 2026.
Read the summary - Medium impact
Emcure Pharmaceuticals Subsidiary Gennova Sells mRNA Business for ₹1,395 Million
Emcure Pharmaceuticals' subsidiary, Gennova Biopharmaceuticals, is selling its mRNA business to Immunoscript Life Science for ₹1,395 Million via slump sale. The business contributed ₹647.10 Million revenue in FY26. Completion is expected by July 17, 2026. This is a strategic move to reorganize Gennova's operations.
Read the summary - Medium impact
Emcure Pharmaceuticals Subsidiary Acquires Full Stake in Mantra Pharma for CAD $50 Million
Emcure Pharmaceuticals' subsidiary, Marcan, will acquire full ownership of step-down subsidiary Mantra Pharma Inc. by purchasing all Class E Special Shares for CAD $50 million. The transaction is set to complete on July 03, 2026. Mantra Pharma Inc. reported a FY26 turnover of CAD $96.67 million.
Read the summary - Low impact
Emcure Pharmaceuticals: President - API Business, Kuber Jagdale, Retires
Mr. Kuber Jagdale, President – API Business at Emcure Pharmaceuticals, will retire due to superannuation on June 30, 2026. This marks a change in senior management, with his cessation effective at the close of business hours on that date.
Read the summary - Low impact
Emcure Pharmaceuticals Announces Trading Window Closure for Q1 FY27 Results
Emcure Pharmaceuticals Limited will close its trading window from July 01, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. The board meeting date for results approval will be intimated later.
Read the summary - Low impact
Emcure Promoters Declare No New Encumbrance on Shares for FY26
Emcure Pharmaceuticals promoters declared no new encumbrances on their shares for FY26. An existing pledge of 60,000 shares by promoter group member Smita Paresh Shah from FY24-25 continues as of March 31, 2026. The company submitted the declaration as per SEBI Takeover Regulations.
Read the summary - High impact
Emcure Pharmaceuticals FY26 Revenue Surges 16.6% to ₹9,204 Crore; PAT Jumps 33.1%
Emcure Pharmaceuticals reported FY26 revenue of ₹9,204 crore, up 16.6% YoY. PAT increased 33.1% to ₹941 crore. EBITDA grew 21.8% to ₹1,789 crore with margins at 19.4%. International business showed strong growth, contributing ₹5,177 crore. The company highlighted its robust product pipeline and strategic partnerships.
Read the summary - Low impact
Emcure Pharmaceuticals Allots 70,000 Equity Shares Under ESOP Scheme
Emcure Pharmaceuticals allotted 70,000 equity shares of Rs. 10 each under its ESOP Scheme 2013. This allotment increases the company's issued and paid-up share capital to 18,96,59,547 equity shares.
Read the summary - Low impact
Emcure Pharmaceuticals to Participate in Multiple Investor Meetings from May 26 to June 9
Emcure Pharmaceuticals announced its participation in multiple investor meetings and conferences. The events are scheduled from May 26, 2026, to June 9, 2026, involving engagements with Ambit Capital, 360 ONE Capital, Axis Capital, and ICICI Securities. No unpublished price-sensitive information will be shared.
Read the summary - Low impact
Emcure Pharmaceuticals to Participate in Multiple Investor Conferences in May-June 2026
Emcure Pharmaceuticals will participate in investor meetings from May 26 to June 9, 2026. Events include the Ambit Capital Titans of Tomorrow Conference, 360 ONE Capital Annual Investor Conference, Axis Capital Rising Stars Conference, and ICICI Securities India Investor Conference. No price-sensitive information will be shared.
Read the summary - Low impact
Emcure Pharmaceuticals to Participate in Multiple Investor Conferences in May-June 2026
Emcure Pharmaceuticals will attend multiple investor conferences from May 26 to June 9, 2026. Events include Ambit Capital, 360 ONE Capital, Axis Capital, and ICICI Securities conferences. No price-sensitive information will be disclosed.
Read the summary - Low impact
Emcure Pharmaceuticals to Participate in Multiple Investor Meetings in May-June 2026
Emcure Pharmaceuticals will participate in several investor meetings and conferences from May 26 to June 9, 2026. These include events hosted by Ambit Capital, 360 ONE Capital, Axis Capital, and ICICI Securities. No unpublished price-sensitive information will be disclosed.
Read the summary - Medium impact
Emcure Pharmaceuticals: US FDA inspects Sanand facility, issues 7 procedural observations
Emcure Pharmaceuticals' Sanand facility was inspected by the US FDA from May 6-15, 2026. The inspection resulted in 7 procedural observations noted on a Form 483. The company is addressing these observations and will respond to the FDA within the given timeframe.
Read the summary - Medium impact
Emcure Pharmaceuticals Q4 FY26 Earnings Call Transcript Released
Emcure Pharmaceuticals reported Q4 FY26 results with revenue up 16.7% to ₹2,470 crores and full-year revenue at ₹9,204 crores (up 16.6%). Adjusted PAT grew 36% in Q4 to ₹279 crores and 41% for the full year to ₹1,008 crores. The company surpassed $1 billion in revenue for FY26. Key partnerships were formed with Novo Nordisk and Sanofi. FY27 revenue growth is projected at low to mid-teen.
Read the summary - Low impact
Emcure Pharmaceuticals Assigned ESG Rating of 21 for FY25
Emcure Pharmaceuticals Limited received an ESG rating of 21 for FY24-25 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned independently based on publicly available information.
Read the summary - Low impact
Emcure Pharmaceuticals Publishes Audited Financial Results for FY26 Ended March 31
Emcure Pharmaceuticals Limited published its audited financial results for the quarter and year ended March 31, 2026. The results were published in "Financial Express" and "Loksatta" on May 06, 2026, and are also available on the company's website.
Read the summary - Low impact
Emcure Pharmaceuticals releases audio recording of Q4 FY26 earnings call
Emcure Pharmaceuticals has released the audio recording of its Q4 FY26 earnings call, held on May 05, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Emcure Pharma Re-appoints Dr. Mukund Gurjar and Satish Mehta as Directors
Emcure Pharmaceuticals re-appointed Dr. Mukund Gurjar as Whole-time Director from August 28, 2026, for one year. Satish Mehta was re-appointed as Managing Director for five years from April 01, 2027. Both appointments are subject to shareholder approval.
Read the summary - Low impact
Emcure Pharma Re-appoints Dr. Mukund Gurjar & Mr. Satish Mehta as Directors
Emcure Pharmaceuticals has re-appointed Dr. Mukund Gurjar as Whole-time Director for one year from August 28, 2026. Mr. Satish Mehta has been re-appointed as Managing Director for five years from April 01, 2027. Both appointments are subject to shareholder approval.
Read the summary - High impact
Emcure Pharmaceuticals FY26 Revenue Crosses $1 Bn, Up 16.6% to ₹9,204 Crore
Emcure Pharmaceuticals reported FY26 revenue of ₹9,204 crore, a 16.6% increase, crossing the US$1 billion mark. Q4 FY26 revenue was ₹2,470 crore (up 16.7%). Adjusted PAT grew over 40% for FY26. Strategic initiatives included Zuventus consolidation and European/Canadian acquisitions. International business grew 22.2%.
Read the summary - Medium impact
Emcure Pharmaceuticals Board Approves FY26 Audited Results, Recommends Dividend, and Reappoints Directors
Emcure Pharmaceuticals' Board approved FY26 audited results. A final dividend of ₹3.60 per share is recommended. Dr. Mukund Gurjar re-appointed as Whole-time Director for one year from August 28, 2026. Mr. Satish Mehta re-appointed as Managing Director for five years from April 01, 2027.
Read the summary - Low impact
Emcure Pharmaceuticals Schedules Q4 FY26 Earnings Call for May 5, 2026
Emcure Pharmaceuticals will host an earnings call on May 5, 2026, at 3:30 p.m. IST to discuss its audited financial results for Q4 FY26. Both standalone and consolidated figures for the quarter and year ended March 31, 2026, will be reviewed.
Read the summary - Low impact
Emcure Pharma Appoints Mr. C S Muralidharan as Independent Director
Emcure Pharmaceuticals Limited appointed Mr. C S Muralidharan as an Independent Director for a three-year term starting April 1, 2026. The appointment was approved by shareholders via postal ballot, with results announced on April 27, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio